CABA

In a report released today, Vamil Divan from Mizuho Securities maintained a Buy rating on Cabaletta Bio (CABA – Research Report), with a price target of $20.00. The company's shares closed last Wednesday at $1.66, close to its 52-week low of $1.17. According to TipRanks.com, Divan is a 3-star analyst with an average return of 1.0% and a 52.0% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals. Cabaletta Bio has an analyst consensus of Strong Buy, with a price target consensus of $15.33, representing a 791.3% upside. In a report issued on May 16, H.C.
https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-a-buy-rating-on-cabaletta-bio-caba?utm_source=advfn.com&utm_medium=referral